<DOC>
	<DOCNO>NCT02291809</DOCNO>
	<brief_summary>The primary objective compare &amp; evaluate treatment group change decline/reduction HIV viral load &amp; increase change WBC white blood cell count adult Remune dose v low dose Remune placebo group . Additional objective include change CD4+ &amp; CD8+ T cell count along increase HIV immunity .</brief_summary>
	<brief_title>REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety &amp; Efficacy Clinical Study</brief_title>
	<detailed_description>This 26 subject Multi Center double-blind randomized , Safety &amp; Efficacy , pediatric HIV/AIDS Phase II study , primarily evaluate safety efficacy HIV-1 immunogen secondarily examine change CD4+ &amp; CD8+ T cell count , determine Remune vaccine effect multiple inoculation HIV-1 immunogen viral replication child HIV-1 infection &amp; immunogenicity Remune . Multi-center , randomize , double-blind , placebo-controlled , two arm parallel design study Remune .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children clinically diagnose HIV 3 month age age 16 year old Subjects approve FDA antiviral medication except triple cocktail HAART drug Truvada Triple cocktail HAART drug Healthy subject</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HIV-1 Immunogen</keyword>
</DOC>